Researchers have discovered a new way to make immunotherapy work against pancreatic cancer by targeting so-called cryptic peptides. These peptides come from parts of DNA that normally do not make proteins, sometimes called the “dark genome.” Cancer cells, however, often use these regions, creating abnormal peptides that do not appear in healthy tissue.
The researchers identified about 500 cryptic peptides that were found only in pancreatic tumors. Because these peptides are much more common than the usual cancer mutations, they give the immune system many more clear signals to recognize and attack the tumor.
To test this idea, the team engineered T cells to recognize these cryptic peptides. In laboratory experiments, the modified T cells successfully detected and destroyed tumor organoids grown from real patient cells. In mouse models, the same T cells significantly slowed the growth of aggressive pancreatic tumors.
These findings open the door to new types of treatments. Because many cryptic peptides are shared across patients, they could be used to develop T cell–based therapies, cancer vaccines, or antibody treatments that guide immune cells directly to pancreatic cancer. This approach offers new hope for improving immunotherapy in a cancer that has long resisted immune-based treatments.